Please note: this event has been postponed due to illness. We anticipate rescheduling the event for late April/early May. The event information will be updated with a new date when one is available.
From Academia to Industry:
Personal Experiences from Bayer leaders Chandra Ramanathan, PhD, MBA and Marion Hitchcock, PhD
Chandra Ramanathan, PhD, MBA / Head, East Coast Innovation Center / Bayer
Marion Hitchcock, PhD / Strategic Alliance Manager – Global External Innovations & Alliances / BayerHealthcare, LLC
David Greenwald, PhD / Director of Corporate Relations / Johns Hopkins Technology Ventures
Hopkins is excited to welcome Drs. Ramanathan and Hitchcock, two leaders from Bayer who will be sharing details of their transition from academia to industry. Dr. Ramanathan has 20 years of experience across the product discovery, development, and commercialization spectrum, while Dr. Hitchcock brings more than 10 years of experience at Bayer in roles ranging from scientist to managing key partnerships for the company. In addition to sharing their personal experiences, Drs. Ramanathan and Hitchcock will also provide insights into Bayer’s Open Innovation platform, which offers opportunities for funding, mentoring, and other forms of collaboration with Bayer and is available to anyone from individuals to start-ups to research organizations. To share insights pertaining to academic-industry partnerships, Dr. David Greenwald, Director of Corporate Relations at Johns Hopkins Technology Ventures, will join the panel discussion.
Chandra Ramanathan is the VP and Head of East Coast Innovation Center at Bayer. In his current role, Chandra is responsible for establishing the innovation center, building an innovative product portfolio with key academic partners, driving external scientific leadership and engaging/collaborating with members of the local innovation ecosystem. In his earlier role, he was with the corporate innovation strategy as the global lead for External Innovation - Life Sciences with focus on new sourcing models (open innovation), venture capital strategy and engagement strategies at global innovation hotspots.
Prior to this role, Chandra was the Global Launch Team leader of Copanlisib and Head of Pipeline Marketing. He was the co-chair of the Value Strategy Team to ensure customer insights (physicians, payer and patients) are incorporated as part of development strategies. He also developed the commercial foundation for companion diagnostics development.
Before joining Bayer he has worked in different roles at Wyeth (Pfizer) and Bristol-Myers Squibb such as Global Brand Team Leader, Licensing/Business Development, Neuroscience Strategy, Drug discovery and Applied Genomics.
Chandra has worked across the pharmaceutical product development and commercialization spectrum for more than 20 years. He has broad commercial and research backgrounds with an M.B.A from the Columbia Business School, Ph.D. in Genomics/Bioinformatics, M.S. in Medicinal Chemistry and B.S. in Pharmacy.
Marion Hitchcock is a Strategic Alliance Manager in Bayer’s Global External Innovation & Alliances group. The function’s mission is to provide access to innovation and generate value through innovative partnering and alliance management. The function serves Drug Discovery in Bayer Healthcare. In her current role Marion is responsible for the Strategic Partnership with the Johns Hopkins University, in particular for the ophthalmic research collaboration with the Wilmer Eye Institute, where she oversees a portfolio of 6 joint projects aiming at new therapeutics for retinal diseases. Additionally, Marion is currently organizing a ‘Bayer Life Science Workshop’ in the field of Radiation Therapy & ImmunoOncology to be hosted at the Johns Hopkins University in March 2017. Based at Bayer’s East Coast Innovation Center in Cambridge/MA, Marion is also involved in establishing the new innovation center and engaging with key academic partners as well as members of the local innovation ecosystem.
Over the past 16 years, Marion has held various positions in R&D at Bayer, giving her a broad research and drug development background. In her earlier role Marion was with Strategy & Portfolio Management as the responsible Franchise Manager for Bayer’s Cardiology & Thrombosis portfolio. Prior to this role, Marion had an active scientific career for over 10 years, as a lab head and project leader in Bayer’s Medicinal Chemistry department in Berlin/Germany, where she gained significant experience in Bayer’s Drug Discovery process along the whole value chain, from target discover and validation to lead optimization and transition to clinical development. During this period she has worked on research projects in the fields of Fertility Control, Dermatology/Inflammation, Immunology, Oncology, Cardiology/Thrombosis, Ophthalmology, as well as customized software design.
Marion received her Ph.D. in Organic Chemistry from the Technical University Berlin/Germany, in 1998. Thereafter she conducted her postdoctoral research at the Scripps Research Institute at La Jolla, California and started her scientific industrial career at Bayer in 2000.
David Greenwald currently serves as Director of Corporate Relations for Johns Hopkins Technology Ventures (JHTV). Dr. Greenwald is a founder of Relay Technology Management, Inc. and co-inventor of the Relay Innovation Engine software. Dr. Greenwald was previously Chief Executive Officer of Relay Technology Management and Director of Client Solutions for Decision Resources Group (DRG) after its acquisition of Relay. Dr. Greenwald was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked with the Food and Drug Administration on 510(k) applications for diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and was awarded an NIH Ruth L. Kirschstein National Research Service Award (NRSA) towards his Ph.D. research dissertation on gene therapy for Retinitis Pigmentosa, which he completed at Tufts University School of Medicine. Dr. Greenwald lectures on Entrepreneurial Finance and Corporate Finance at The Johns Hopkins Carey Business School, where he is an adjunct faculty.